Roche - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: Roche reported a 58 percent increase in first-half profit to $5.2 billion, helped by lower costs associated with the integration of Genentech. But the numbers fell short of expectations, and a drop in pharma sales of 2.3 percent had analysts moaning. "The results are not really that positive," Rahn & Bodmer's Birgit Kulhoff tells Bloomberg.

Roche's Q2 Highlights

  • Group first-half sales up 5% in local currencies (3% in Swiss francs, 7% in US dollars) to 24.6 billion Swiss francs.
  • Operating profit (before exceptional items) up significantly, rising 11% in local currencies (10% in Swiss francs) to 8.8 billion Swiss francs - again advancing faster than sales.
  • Net income rises 37% compared with first half of 2009; lower exceptional expenses relating to integration of Genentech.
  • Core earnings per share up 11% in local currencies, 9% in Swiss francs.
  • Full-year outlook for 2010 confirmed.

Roche's website:
Full release: Roche earnings release

Roche - Big Pharma's Q2 2010 Earnings Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.